Health Catalyst director granted 7,562 RSUs

Health Catalyst, Inc. reported that director Duncan Gallagher received a grant of 7,562 shares of common stock in the form of restricted stock units under the company’s 2019 Stock Option and Incentive Plan.

Rhea-AI Filing Summary

Health Catalyst, Inc. reported that director Duncan Gallagher received a grant of 7,562 shares of common stock in the form of restricted stock units under the company’s 2019 Stock Option and Incentive Plan. Following this award, his directly held common stock holdings total 132,023 shares. According to the award terms and the non-employee director compensation policy, 100% of these RSUs vested on February 17, 2026, meaning each unit has already converted into one share of common stock, subject to the plan’s conditions.

Insider Trade Summary

Grant/Award: 7,562 shares

Grant/Award 1 txn

Insider Gallagher Duncan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,562	$0.00	$0.00

Holdings After Transaction: Common Stock — 132,023 shares (Direct)

Footnotes (1)

1. F1. Represents an award of the Issuer's restricted stock units ("RSUs") granted pursuant to the Issuer's 2019 Stock Option and Incentive Plan (the "2019 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan and in accordance with the terms of Issuer's Non-Employee Director Compensation Policy, 100% of such RSUs vested on February 17, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Health Catalyst (HCAT) disclose for Duncan Gallagher?

Health Catalyst disclosed that director Duncan Gallagher received a grant of 7,562 restricted stock units, each representing one share of common stock. The grant was made under the 2019 Stock Option and Incentive Plan and fully vested on February 17, 2026.

How many Health Catalyst (HCAT) shares does Duncan Gallagher hold after this award?

After the award, Duncan Gallagher directly holds 132,023 shares of Health Catalyst common stock. This total includes the 7,562 shares delivered through fully vested restricted stock units granted under the company’s 2019 Stock Option and Incentive Plan.

Was Duncan Gallagher’s Health Catalyst (HCAT) award an open-market stock purchase?

No, the transaction was not an open-market purchase. It was a grant of 7,562 restricted stock units under Health Catalyst’s 2019 Stock Option and Incentive Plan, classified as a grant, award, or other acquisition with a reported price per share of $0.0000.

What are the key terms of Duncan Gallagher’s RSU grant at Health Catalyst (HCAT)?

The award consists of 7,562 restricted stock units, each equal to one share of common stock. The grant was issued under the 2019 Stock Option and Incentive Plan and, per the non-employee director compensation policy, 100% of the RSUs vested on February 17, 2026.

Under which plan was Duncan Gallagher’s Health Catalyst (HCAT) equity award granted?

The equity award was granted under Health Catalyst’s 2019 Stock Option and Incentive Plan. The plan governs restricted stock units like this 7,562-unit grant and sets conditions including vesting and settlement into common stock for non-employee directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 07:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gallagher Duncan

(Last) (First) (Middle)

C/O HEALTH CATALYST, INC.

10897 SOUTH RIVER FRONT PARKWAY, #300

(Street)

SOUTH JORDAN UT 84095

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Health Catalyst, Inc. [ HCAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		7,562(1)	A	$0.00	132,023	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of the Issuer's restricted stock units ("RSUs") granted pursuant to the Issuer's 2019 Stock Option and Incentive Plan (the "2019 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan and in accordance with the terms of Issuer's Non-Employee Director Compensation Policy, 100% of such RSUs vested on February 17, 2026.

Remarks:

	/s/Benjamin Landry, as Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.